IL6R and rheumatoid arthritis: Particularly, the treatment of Covid19 patients with Tocilizumab, a recombinant humanized monoclonal antibody against the soluble and membrane-bound Interleukin-6 receptor (IL-6R), already approved for rheumatoid arthritis, successfully reduced the mortality rate (Zhang et al., 2020).